vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.
BYLINE BANCORP, INC. is the larger business by last-quarter revenue ($112.4M vs $85.1M, roughly 1.3× 4D Molecular Therapeutics, Inc.). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs 22.8%, a 10.6% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 9.0%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 6.4%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
BY vs FDMT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $85.1M |
| Net Profit | $37.6M | $19.4M |
| Gross Margin | — | — |
| Operating Margin | — | 17.3% |
| Net Margin | 33.4% | 22.8% |
| Revenue YoY | 9.0% | 8508900.0% |
| Net Profit YoY | 33.0% | 139.1% |
| EPS (diluted) | $0.83 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $85.1M | ||
| Q3 25 | $115.7M | $90.0K | ||
| Q2 25 | $110.5M | $15.0K | ||
| Q1 25 | $103.1M | $14.0K | ||
| Q4 24 | $104.7M | $1.0K | ||
| Q3 24 | $101.8M | $3.0K | ||
| Q2 24 | $99.4M | $5.0K |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $19.4M | ||
| Q3 25 | $37.2M | $-56.9M | ||
| Q2 25 | $30.1M | $-54.7M | ||
| Q1 25 | $28.2M | $-48.0M | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $30.3M | $-43.8M | ||
| Q2 24 | $29.7M | $-35.0M |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | 17.3% | ||
| Q3 25 | 43.1% | -67983.3% | ||
| Q2 25 | 35.2% | -396373.3% | ||
| Q1 25 | 36.4% | -383007.1% | ||
| Q4 24 | 38.6% | — | ||
| Q3 24 | 39.3% | -1704400.0% | ||
| Q2 24 | 40.4% | -849120.0% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | 22.8% | ||
| Q3 25 | 32.1% | -63195.6% | ||
| Q2 25 | 27.2% | -364386.7% | ||
| Q1 25 | 27.4% | -342657.1% | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 29.8% | -1461433.3% | ||
| Q2 24 | 29.9% | -699060.0% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $0.43 | ||
| Q3 25 | $0.82 | $-1.01 | ||
| Q2 25 | $0.66 | $-0.98 | ||
| Q1 25 | $0.64 | $-0.86 | ||
| Q4 24 | $0.68 | — | ||
| Q3 24 | $0.69 | $-0.79 | ||
| Q2 24 | $0.68 | $-0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $402.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $505.7M |
| Total Assets | $9.9B | $566.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $402.7M | ||
| Q3 25 | $259.0M | $305.1M | ||
| Q2 25 | $218.3M | $293.2M | ||
| Q1 25 | $421.3M | $321.4M | ||
| Q4 24 | $563.1M | $424.9M | ||
| Q3 24 | $452.6M | $501.9M | ||
| Q2 24 | $730.5M | $541.9M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $505.7M | ||
| Q3 25 | $1.2B | $369.0M | ||
| Q2 25 | $1.2B | $420.9M | ||
| Q1 25 | $1.1B | $469.7M | ||
| Q4 24 | $1.1B | $510.6M | ||
| Q3 24 | $1.1B | $552.9M | ||
| Q2 24 | $1.0B | $588.3M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $566.7M | ||
| Q3 25 | $9.8B | $424.0M | ||
| Q2 25 | $9.7B | $473.6M | ||
| Q1 25 | $9.6B | $515.7M | ||
| Q4 24 | $9.5B | $560.4M | ||
| Q3 24 | $9.4B | $604.0M | ||
| Q2 24 | $9.6B | $620.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $28.6M |
| Free Cash FlowOCF − Capex | — | $28.5M |
| FCF MarginFCF / Revenue | — | 33.5% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-109.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $28.6M | ||
| Q3 25 | $38.3M | $-46.5M | ||
| Q2 25 | $16.3M | $-43.4M | ||
| Q1 25 | $27.1M | $-47.8M | ||
| Q4 24 | $175.2M | $-134.6M | ||
| Q3 24 | $19.8M | $-29.4M | ||
| Q2 24 | $40.1M | $-30.2M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $28.5M | ||
| Q3 25 | $38.0M | $-46.6M | ||
| Q2 25 | $15.2M | $-43.4M | ||
| Q1 25 | $25.0M | $-48.4M | ||
| Q4 24 | $171.2M | $-138.4M | ||
| Q3 24 | $19.1M | $-31.2M | ||
| Q2 24 | $39.4M | $-30.6M |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | 33.5% | ||
| Q3 25 | 32.8% | -51765.6% | ||
| Q2 25 | 13.7% | -289620.0% | ||
| Q1 25 | 24.3% | -345635.7% | ||
| Q4 24 | 163.5% | -13837100.0% | ||
| Q3 24 | 18.8% | -1038966.7% | ||
| Q2 24 | 39.7% | -611840.0% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 0.1% | ||
| Q3 25 | 0.3% | 101.1% | ||
| Q2 25 | 1.0% | 440.0% | ||
| Q1 25 | 2.0% | 4507.1% | ||
| Q4 24 | 3.8% | 378600.0% | ||
| Q3 24 | 0.6% | 59266.7% | ||
| Q2 24 | 0.7% | 6980.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | 1.47× | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 1.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
